TTR and breast cancer: Out of 190 patients with BC, 51% were negative and 49% were positive for pathogenic mutations, with the percentages as follows: 29.8% BRCA1, 17% BRCA2, 16% CHECK2, 14% RAD Group (RAD51C and RAD51D), 7% PALB, 6% NBN, 3% TP53 and ATM and 2% BARD1.